Buparvaquone Injection
- Packing: 2 ml, 20 ml Vial
- Available Strength : 50 Mg/Ml
Description
Product Description: Buparvaquone Injection is a sterile solution containing buparvaquone, an antiprotozoal medication. It is formulated for intravenous administration and is indicated for the treatment of bovine theileriosis caused by Theileria annulata and ovine theileriosis caused by Theileria lestoquardi.
Indications and Usage: Buparvaquone Injection is indicated for the treatment of bovine theileriosis (tropical theileriosis) caused by Theileria annulata in cattle and ovine theileriosis (malignant ovine theileriosis) caused by Theileria lestoquardi in sheep. It is effective in reducing the severity of clinical signs and the level of parasitemia associated with these diseases.
Dosage and Administration: The recommended dosage of Buparvaquone Injection varies depending on the severity of the theileriosis infection, the species of animal, and the individual animal's response to treatment. It is typically administered as a single intravenous injection at a dose of 2.5 mg/kg body weight in cattle and 5 mg/kg body weight in sheep.
Dosage Forms and Strengths: Buparvaquone Injection is available as a sterile solution in vials or ampules. The strength of the solution is typically expressed in milligrams of buparvaquone per milliliter (mg/mL), with various concentrations available to accommodate different dosing regimens.
Contraindications: Buparvaquone Injection is contraindicated in animals with known hypersensitivity to buparvaquone or any component of the formulation. It should not be used in pregnant animals, as safety in gestating animals has not been established.
Warnings and Precautions: Use caution when administering Buparvaquone Injection in animals with pre-existing liver or kidney dysfunction, as buparvaquone is primarily metabolized in the liver and excreted via the kidneys. Monitor animals closely for signs of adverse reactions, including local injection site reactions, gastrointestinal disturbances, and hypersensitivity reactions.
Adverse Reactions/Side Effects: Common adverse reactions associated with Buparvaquone Injection may include transient local irritation or inflammation at the injection site, gastrointestinal upset (such as vomiting or diarrhea), and allergic reactions (such as itching, hives, or swelling). Rare but serious adverse reactions may include anaphylaxis or other severe hypersensitivity reactions.
Drug Interactions: There are no known drug interactions with Buparvaquone Injection. However, caution should be exercised when administering other medications concurrently, as the safety and efficacy of concurrent therapy have not been established.
Use In Specific Populations Description: Safety and efficacy of Buparvaquone Injection in pregnant or lactating animals have not been established. Use caution and consult with a veterinarian before administering Buparvaquone Injection to animals in these populations.
How Supplied/Storage and Handling: Buparvaquone Injection is supplied as a sterile solution in vials or ampules for intravenous administration. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to ensure proper storage and handling to maintain the integrity of the product. Unused portions should be discarded according to standard procedures for biohazardous waste.
